Tag: Prostate cancer treatment

In 2022, an estimated 24,600 men in Canada were diagnosed with prostate cancer, making it the most common cancer among Canadian men [1.4.5]. For those with advanced disease, a key question is: **how long can you stay on Orgovyx?** This is determined by efficacy and tolerability.

As of January 2025, the list price for a 30-day supply of Orgovyx is $2,762.36, though the actual amount a patient pays can vary drastically based on their insurance coverage and eligibility for financial assistance. Understanding how much does a 30 day supply of Orgovyx cost requires looking beyond the official list price to consider all available programs and discounts.

The FDA approved Orgovyx (relugolix) in 2020, introducing the first oral gonadotropin-releasing hormone (GnRH) antagonist for advanced prostate cancer. For patients seeking what is the alternative to Orgovyx, several other effective androgen-deprivation therapies are available, including injectable GnRH agonists and different types of hormone-targeting agents. These alternatives vary in their mechanism of action, administration route, side effects, and cost, making the choice a personalized decision based on a patient's health and treatment goals.

Clinical studies show ELIGARD (leuprolide acetate) is highly effective, with trials demonstrating that over 94% of patients achieve target testosterone suppression levels within a month of the first injection [2.3.1]. What is the success rate of ELIGARD? It is primarily measured by its ability to lower testosterone to castrate levels.

Prostate cancer affects about 1 in 8 men in the U.S., with hormone therapy being a cornerstone of treatment for advanced cases. A common question that arises for patients is, **is Eligard generic for Lupron?** While they share similarities, they are not identical.

As many as 95% of patients with prostate cancer can achieve castrate-level testosterone suppression within a month of starting Lupron. Understanding **how do you know if Lupron is working** is crucial for patients, but the signs of success depend on the condition being treated and require patience through an initial hormonal surge.

In clinical trials, abiraterone acetate significantly extended overall survival for patients with metastatic castration-resistant prostate cancer. As a hormonal therapy, it works by targeting the body's androgen production, which fuels prostate cancer growth. What is the mechanism of abiraterone, and how does this selective approach help combat advanced prostate cancer?

Between 5 and 10 million Americans were exposed to diethylstilbestrol (DES) before the FDA advised against its use in pregnant women in 1971 [1.3.4, 1.5.5]. So, is diethylstilbestrol still used today? While largely discontinued, it has very limited applications.

According to the National Cancer Institute, Orgovyx, also known by its generic name relugolix, is a drug used to treat adults with advanced prostate cancer. It represents the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for this condition, offering a new and convenient treatment approach.

Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most prostate cancer cells, with levels increasing in more advanced and aggressive disease. A **PSMA antibody drug** is a specialized therapy that leverages this protein to selectively target and destroy cancer cells while minimizing harm to healthy tissue. This article explains how this precision medicine works, who can benefit, and its potential side effects.